Compare MXCT & YOOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MXCT | YOOV |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | Singapore |
| Employees | N/A | 109 |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Diversified Commercial Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.0M | 158.7M |
| IPO Year | 2021 | 2025 |
| Metric | MXCT | YOOV |
|---|---|---|
| Price | $1.11 | $0.50 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $5.50 | N/A |
| AVG Volume (30 Days) | 1.7M | ★ 3.3M |
| Earning Date | 05-12-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $33,026,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $18.50 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.64 | $0.36 |
| 52 Week High | $2.31 | $1.11 |
| Indicator | MXCT | YOOV |
|---|---|---|
| Relative Strength Index (RSI) | 38.61 | 49.98 |
| Support Level | $1.08 | $0.44 |
| Resistance Level | $1.16 | $0.79 |
| Average True Range (ATR) | 0.09 | 0.16 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 6.10 | 18.65 |
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
Concorde International Group Ltd is an integrated security services provider that combines physical manpower and technology to deliver effective security solutions. The company offers a range of services to enhance security and safety: (1) i-Guarding Services; (2) Man-Guarding Services; and (3) Consultancy and Training Services. Its i-Guarding Services leverages technology to increase efficiency, with a mobile platform and cluster aggregation model of a higher skillset workforce. It has two operating segments, which are (i) security services; and (ii) training school. The Majority revenue is generated from Security Services.